Moberg Pharma (MOB) Stora Aktiedagarna 2026 summary

Product innovation and clinical results

• TerclaraⓇ is a novel topical terbinafine treatment for mild to moderate nail fungus, delivering the gold standard antifungal directly to the nail with significantly lower systemic exposure compared to oral therapy.

• Achieved a 76% mycological cure rate in Phase II & III studies, outperforming other OTC treatments with typical cure rates around 20%.

• Offers visible improvement, safety, ease of application, and rapid results, as confirmed by patient surveys.

Market performance and expansion

• Approved in 13 European countries with ongoing rollout and additional approvals in the pipeline.

• Became market leader in Sweden and Norway within the first two years, driving category growth and achieving significant value and volume shares.

• Awarded 'Launch of the Year 2024' in Sweden and nominated for the same in Norway, recognized for revitalizing the category and strong sales.

• Partners established for Europe, Canada, Scandinavia, and Israel, including Karo Healthcare for broad distribution.

Market opportunity and growth drivers

• Over 70 million Europeans affected by nail fungus, with 10% prevalence and many doctors avoiding oral terbinafine due to side effects.

• Global onychomycosis market estimated at $2 billion, with growth driven by high prevalence, aging population, lifestyle factors, and rising awareness.

• TerclaraⓇ expands the market by converting non-treaters and dissatisfied users, unlocking further growth potential.